CLL Clinical Trial
Official title:
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. They have shorter life expectancy compared to healthy people. There is an urgent need for new treatment to prolong participant life and control disease-related symptoms. In this study, participants with CLL, without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is considered a standard first line treatment or receive sonrotoclax plus zanubrutinib. It is hypothesized that sonrotoclax plus zanubrutinib may be better than venetoclax plus obinutuzumab in treating CLL. The main purpose of this study is to compare the duration the participants live without the CLL getting worse between participants who received venetoclax plus obinutuzumab versus sonrotoclax plus zanubrutinib. Approximately 640 participants will be included in this study around the world. Participants will have equal chance to be allocated to receive either of the treatment combinations. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02229422 -
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01862445 -
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
|
||
| Completed |
NCT00535873 -
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
|
Phase 2 | |
| Withdrawn |
NCT03639324 -
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
|
Phase 1 | |
| Recruiting |
NCT05517265 -
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
|
||
| Recruiting |
NCT03868722 -
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04640909 -
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients
|
N/A | |
| Recruiting |
NCT05610228 -
Study of the Metabolism in the Lymphatic Niche of CLL
|
||
| Completed |
NCT01168921 -
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 | |
| Withdrawn |
NCT05209308 -
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
|
Phase 2 | |
| Completed |
NCT00792077 -
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
|
Phase 2 | |
| Recruiting |
NCT05246345 -
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
|
||
| Terminated |
NCT01532635 -
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
|
Phase 2 | |
| Completed |
NCT01703364 -
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
|
Phase 1/Phase 2 | |
| Terminated |
NCT03572634 -
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
|
Phase 1/Phase 2 | |
| Completed |
NCT03231579 -
Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
|
||
| Completed |
NCT00636909 -
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT03524235 -
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
|
Phase 1 | |
| Active, not recruiting |
NCT04746092 -
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19
|